Personalized P2Y12 Inhibitor Treatment Are We Ready to Go?

被引：2
|
作者：
ten Berg, Jurrien M. [1 ]
Janssen, Paul W. A. [1 ]
机构：
[1] St Antonius Hosp, Dept Cardiol, POB 2500, NL-3432 Nieuwegein, Netherlands
来源：
JACC-CARDIOVASCULAR INTERVENTIONS | 2020年 / 13卷 / 05期
关键词：
CYP2C19; genotyping; P2Y(12) inhibitors; tailored treatment; CLOPIDOGREL;
D O I：
10.1016/j.jcin.2020.01.221
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：631 / 633
页数：3
相关论文
共 50 条
  • [31] P2Y12 Inhibitor Monotherapy vs. Dual Antiplatelet Therapy
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (05) : 1156 - 1156
  • [32] P2Y12 Inhibitor Adherence Patterns in Patients with Acute Coronary Syndrome
    Ozaki, Aya
    Ko, Dennis T.
    Chong, Alice
    Fang, Jiming
    Austin, Peter
    Sud, Maneesh
    Jackevicius, Cynthia A.
    CIRCULATION, 2021, 144
  • [33] Trajectories of P2Y12 inhibitor adherence in patients with acute coronary syndromes
    Moon, Jungyeon
    Ozaki, Aya F.
    Chong, Alice
    Sud, Maneesh
    Fang, Jiming
    Austin, Peter C.
    Ko, Dennis T.
    Jackevicius, Cynthia A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (01)
  • [34] Factors Influencing Provider and Patient Choice of P2Y12 Inhibitor Therapy
    Benitez, Rebekah M.
    Lusk, Kathleen A.
    Ahmed, S. Hinan
    Hartzell, Stephanie A.
    Kalich, Bethany A.
    JOURNAL OF PHARMACY PRACTICE, 2022, 35 (02) : 235 - 243
  • [35] P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention
    Davide Capodanno
    Usman Baber
    Deepak L. Bhatt
    Jean-Philippe Collet
    George Dangas
    Francesco Franchi
    C. Michael Gibson
    Hyeon-Cheol Gwon
    Adnan Kastrati
    Takeshi Kimura
    Pedro A. Lemos
    Renato D. Lopes
    Roxana Mehran
    Michelle L. O’Donoghue
    Sunil V. Rao
    Fabiana Rollini
    Patrick W. Serruys
    Philippe G. Steg
    Robert F. Storey
    Marco Valgimigli
    Pascal Vranckx
    Hirotoshi Watanabe
    Stephan Windecker
    Dominick J. Angiolillo
    Nature Reviews Cardiology, 2022, 19 : 829 - 844
  • [36] Selatogrel, a novel P2Y12 inhibitor: a review of the pharmacology and clinical development
    Milluzzo, Rocco P.
    Franchina, Gabriele A.
    Capodanno, Davide
    Angiolillo, Dominick J.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (06) : 537 - 546
  • [37] Guided P2Y12 inhibitor therapy after percutaneous coronary intervention
    Sibbing, Dirk
    Kastrati, Adnan
    LANCET, 2021, 397 (10283): : 1423 - 1425
  • [38] Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?
    De Caterina, Raffaele
    Veneri, Alessia Delli
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2016, 35 (06) : 319 - 321
  • [39] Hirudin anticoagulation allows more rapid determination of P2Y12 inhibition by the VerifyNow P2Y12 assay
    Sumaya, Wael
    Daly, Rebecca L.
    Mehra, Sonal
    Dhutia, Amrita J.
    Howgego, Kate E.
    Ecob, Rosemary
    Judge, Heather M.
    Morton, Allison C.
    Storey, Robert F.
    THROMBOSIS AND HAEMOSTASIS, 2013, 109 (03) : 550 - 555
  • [40] New P2Y12 inhibitors for the treatment of coronary artery disease
    Gurbel, P. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 4 - 5
12345